Expression and Clinical Pathological Correlation between miR-155 and C-erbB-2 in Tissues of Patients with Endometrial Cancer

  • Li Jin
Keywords: miR-155; C-erbB-2; Endometrial cancer; Expression; Pathological features

Abstract

To explore the expression levels of miR-155 and C-erbB-2 in cancer tissues of patients with endometrial cancer
and their relationship with clinicopathological features. The endometrial cancer tissues were collected as a
research group, and the tumors of uterine fibroids treated in the same period were collected. The tissue served as
a control group. The expression levels of miR-155 and C-erbB-2 in the two groups were detected by RT-PCR
and immunohistochemistry, and the differences were analyzed. The expression levels of miR-155 and C-erbB-2
in endometrial carcinoma tissues were analyzed. The relationship between clinical features of patients; analysis
of the correlation between miR-155 and C-erbB-2 expression in endometrial cancer tissues. The high expression
rates of miR-155 and C-erbB-2 in endometrial carcinoma tissues were 82.47% (80/97) and 80.41% (78/97),
respectively, which was significantly higher than 13.56% in uterine fibroids (8/59). And 3.39% (2/59), the
difference was statistically significant (P<0.05); the expression level of miR-155 in patients with endometrial
cancer with different FIGO stage, lymph node metastasis and histological type was significantly different.
Statistical significance (P<0.05); the expression level of C-erbB-2 in patients with endometrial cancer with
different FIGO stage and histological type was significantly different, and the difference was statistically
significant (P<0.05); both in the endometrium The expression level in cancer tissues was positively correlated
(P<0.05). miR-155 and C-erbB-2 were highly expressed in endometrial carcinoma tissues; miR-155 was
associated with FIGO stage, lymph node metastasis and histological type; C-erbB-2 and patient FIGO stage and
organization Learning type related; miR-155 and C-erbB-2 were positively correlated in the expression level of
endometrial cancer tissues.

Published
2020-05-01